Pfizer Inc. (NYSE: PFE) said today that it will acquire privately held NextWave Pharmaceuticals. NextWave is a specialty pharmaceutical company that focuses on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders.
The agreement includes recently FDA approved Quillivant XR, which is the first once-daily liquid ADHD treatment in the United States.
Pfizer previously entered into an option and merger agreement with NextWave and made an option payment of $20 million in the second quarter. Pfizer now is exercising its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWave shareholders when the transaction closes. NextWave shareholders are eligible to receive additional payments of up to $425 million, based on certain sales milestones.
The transaction is expected to close during the fourth-quarter of 2012, subject to regulatory approval.
Analysts expect Pfizer to report lower per-share earnings and revenues when it shares it third-quarter results later this month.
Shares of Pfizer are down fractionally in premarket trading to $25.71. The 52-week range is 18.15 to $26.09 and the mean price target is $27.67.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
